Search

Your search keyword '"Ruddy, Kathryn J."' showing total 1,237 results
Start Over Author "Ruddy, Kathryn J."
1,237 results on '"Ruddy, Kathryn J."'

5. Advancing the care of individuals with cancer through innovation & technology: Proceedings from the cardiology oncology innovation summit 2020 and 2021

Author

Brown, Sherry-Ann, Beavers, Craig, Bauer, Brenton, Cheng, Richard K, Berman, Generika, Marshall, Catherine H, Guha, Avirup, Jain, Prantesh, Steward, Austin, DeCara, Jeanne M, Olaye, Iredia M, Hansen, Kathryn, Logan, Jim, Bergom, Carmen, Glide-Hurst, Carri, Loh, Irving, Gambril, John Alan, MacLeod, James, Maddula, Ragasnehith, McGranaghan, Peter J, Batra, Akshee, Campbell, Courtney, Hamid, Abdulaziz, Gunturkun, Fatma, Davis, Robert, Jefferies, John, Fradley, Michael, Albert, Katherine, Blaes, Anne, Choudhuri, Indrajit, Ghosh, Arjun K, Ryan, Thomas D, Ezeoke, Ogochukwu, Leedy, Douglas J, Williams, Wadsworth, Roman, Sebastian, Lehmann, Lorenz, Sarkar, Abdullah, Sadler, Diego, Polter, Elizabeth, Ruddy, Kathryn J, Bansal, Neha, Yang, Eric, Patel, Brijesh, Cho, David, Bailey, Alison, Addison, Daniel, Rao, Vijay, Levenson, Joshua E, Itchhaporia, Dipti, Watson, Karol, Gulati, Martha, Williams, Kim, Lloyd-Jones, Donald, Michos, Erin, Gralow, Julie, and Martinez, Hugo

Published
2024

11. A genome-wide gene-environment interaction study of breast cancer risk for women of European ancestry

Author

Middha, Pooja, Wang, Xiaoliang, Behrens, Sabine, Bolla, Manjeet K, Wang, Qin, Dennis, Joe, Michailidou, Kyriaki, Ahearn, Thomas U, Andrulis, Irene L, Anton-Culver, Hoda, Arndt, Volker, Aronson, Kristan J, Auer, Paul L, Augustinsson, Annelie, Baert, Thaïs, Freeman, Laura E Beane, Becher, Heiko, Beckmann, Matthias W, Benitez, Javier, Bojesen, Stig E, Brauch, Hiltrud, Brenner, Hermann, Brooks-Wilson, Angela, Campa, Daniele, Canzian, Federico, Carracedo, Angel, Castelao, Jose E, Chanock, Stephen J, Chenevix-Trench, Georgia, Cordina-Duverger, Emilie, Couch, Fergus J, Cox, Angela, Cross, Simon S, Czene, Kamila, Dossus, Laure, Dugué, Pierre-Antoine, Eliassen, A Heather, Eriksson, Mikael, Evans, D Gareth, Fasching, Peter A, Figueroa, Jonine D, Fletcher, Olivia, Flyger, Henrik, Gabrielson, Marike, Gago-Dominguez, Manuela, Giles, Graham G, González-Neira, Anna, Grassmann, Felix, Grundy, Anne, Guénel, Pascal, Haiman, Christopher A, Håkansson, Niclas, Hall, Per, Hamann, Ute, Hankinson, Susan E, Harkness, Elaine F, Holleczek, Bernd, Hoppe, Reiner, Hopper, John L, Houlston, Richard S, Howell, Anthony, Hunter, David J, Ingvar, Christian, Isaksson, Karolin, Jernström, Helena, John, Esther M, Jones, Michael E, Kaaks, Rudolf, Keeman, Renske, Kitahara, Cari M, Ko, Yon-Dschun, Koutros, Stella, Kurian, Allison W, Lacey, James V, Lambrechts, Diether, Larson, Nicole L, Larsson, Susanna, Le Marchand, Loic, Lejbkowicz, Flavio, Li, Shuai, Linet, Martha, Lissowska, Jolanta, Martinez, Maria Elena, Maurer, Tabea, Mulligan, Anna Marie, Mulot, Claire, Murphy, Rachel A, Newman, William G, Nielsen, Sune F, Nordestgaard, Børge G, Norman, Aaron, O’Brien, Katie M, Olson, Janet E, Patel, Alpa V, Prentice, Ross, Rees-Punia, Erika, Rennert, Gad, Rhenius, Valerie, Ruddy, Kathryn J, and Sandler, Dale P

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer Genomics, Human Genome, Estrogen, Cancer, Women's Health, Genetics, Prevention, Aging, Breast Cancer, 2.1 Biological and endogenous factors, Adult, Female, Humans, Gene-Environment Interaction, Genetic Predisposition to Disease, Breast Neoplasms, Bayes Theorem, Genome-Wide Association Study, Risk Factors, Polymorphism, Single Nucleotide, Case-Control Studies, Breast cancer, Gene-environment interactions, Genetic epidemiology, European ancestry, CTS Consortium, ABCTB Investigators, kConFab Investigators, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundGenome-wide studies of gene-environment interactions (G×E) may identify variants associated with disease risk in conjunction with lifestyle/environmental exposures. We conducted a genome-wide G×E analysis of ~ 7.6 million common variants and seven lifestyle/environmental risk factors for breast cancer risk overall and for estrogen receptor positive (ER +) breast cancer.MethodsAnalyses were conducted using 72,285 breast cancer cases and 80,354 controls of European ancestry from the Breast Cancer Association Consortium. Gene-environment interactions were evaluated using standard unconditional logistic regression models and likelihood ratio tests for breast cancer risk overall and for ER + breast cancer. Bayesian False Discovery Probability was employed to assess the noteworthiness of each SNP-risk factor pairs.ResultsAssuming a 1 × 10-5 prior probability of a true association for each SNP-risk factor pairs and a Bayesian False Discovery Probability

Published
2023

12. NCCN Guidelines® Insights: Survivorship, Version 1.2022.

Author

Sanft, Tara, Day, Andrew, Peterson, Lindsay, Rodriguez, M Alma, Ansbaugh, Shannon, Armenian, Saro, Baker, K Scott, Ballinger, Tarah, Broderick, Gregory, Demark-Wahnefried, Wendy, Dickinson, Kristin, Fairman, Nathan Paul, Friedman, Debra L, Goldman, Mindy, Henry, Norah Lynn, Hill-Kayser, Christine, Hudson, Melissa, Khakpour, Nazanin, Koura, Divya, McDonough, Allison L, Melisko, Michelle, Mooney, Kathi, Moore, Halle C F, Moryl, Natalie, Neuman, Heather, O'Connor, Tracey, Overholser, Linda, Paskett, Electra D, Patel, Chirayu, Pirl, William, Porpiglia, Andrea, Ruddy, Kathryn J, Schapira, Lidia, Shockney, Lillie, Smith, Sophia, Syrjala, Karen L, Tevaarwerk, Amye, Yang, Eric H, Zee, Phyllis, McMillian, Nicole R, and Freedman-Cass, Deborah A

Abstract

The NCCN Guidelines for Survivorship are intended to help healthcare professionals who work with survivors to ensure that the survivors' complex and varied needs are addressed. The NCCN Guidelines provide screening, evaluation, and treatment recommendations for the consequences of adult-onset cancer and its treatment; recommendations to help promote physical activity, weight management, and immunizations in survivors; and a framework for care coordination. This article summarizes updates to the NCCN Guidelines pertaining to preventive health for cancer survivors, including recommendations about alcohol consumption and vaccinations.

Published
2022

13. Challenges and Opportunities of Epidemiological Studies to Reduce the Burden of Cancers in Young Adults

Author

Nichols, Hazel B., Wernli, Karen J., Chawla, Neetu, O’Meara, Ellen S., Gray, Marlaine Figueroa, Green, Laura E., Anderson, Chelsea, Baggett, Christopher D., Casperson, Mallory, Chao, Chun, Jones, Salene M. W., Kirchhoff, Anne C., Kuo, Tzy-Mey, Lee, Catherine, Malogolowkin, Marcio, Quesenberry, Charles P., Ruddy, Kathryn J., Wun, Ted, Zebrack, Brad, Chubak, Jessica, Hahn, Erin E., Keegan, Theresa H. M., and Kushi, Lawrence H.

Published
2023
Full Text
View/download PDF

19. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

Author

Mueller, Stefanie H., Lai, Alvina G., Valkovskaya, Maria, Michailidou, Kyriaki, Bolla, Manjeet K., Wang, Qin, Dennis, Joe, Lush, Michael, Abu-Ful, Zomoruda, Ahearn, Thomas U., Andrulis, Irene L., Anton-Culver, Hoda, Antonenkova, Natalia N., Arndt, Volker, Aronson, Kristan J., Augustinsson, Annelie, Baert, Thais, Freeman, Laura E. Beane, Beckmann, Matthias W., Behrens, Sabine, Benitez, Javier, Bermisheva, Marina, Blomqvist, Carl, Bogdanova, Natalia V., Bojesen, Stig E., Bonanni, Bernardo, Brenner, Hermann, Brucker, Sara Y., Buys, Saundra S., Castelao, Jose E., Chan, Tsun L., Chang-Claude, Jenny, Chanock, Stephen J., Choi, Ji-Yeob, Chung, Wendy K., Colonna, Sarah V., Cornelissen, Sten, Couch, Fergus J., Czene, Kamila, Daly, Mary B., Devilee, Peter, Dörk, Thilo, Dossus, Laure, Dwek, Miriam, Eccles, Diana M., Ekici, Arif B., Eliassen, A. Heather, Engel, Christoph, Evans, D. Gareth, Fasching, Peter A., Fletcher, Olivia, Flyger, Henrik, Gago-Dominguez, Manuela, Gao, Yu-Tang, García-Closas, Montserrat, García-Sáenz, José A., Genkinger, Jeanine, Gentry-Maharaj, Aleksandra, Grassmann, Felix, Guénel, Pascal, Gündert, Melanie, Haeberle, Lothar, Hahnen, Eric, Haiman, Christopher A., Håkansson, Niclas, Hall, Per, Harkness, Elaine F., Harrington, Patricia A., Hartikainen, Jaana M., Hartman, Mikael, Hein, Alexander, Ho, Weang-Kee, Hooning, Maartje J., Hoppe, Reiner, Hopper, John L., Houlston, Richard S., Howell, Anthony, Hunter, David J., Huo, Dezheng, Ito, Hidemi, Iwasaki, Motoki, Jakubowska, Anna, Janni, Wolfgang, John, Esther M., Jones, Michael E., Jung, Audrey, Kaaks, Rudolf, Kang, Daehee, Khusnutdinova, Elza K., Kim, Sung-Won, Kitahara, Cari M., Koutros, Stella, Kraft, Peter, Kristensen, Vessela N., Kubelka-Sabit, Katerina, Kurian, Allison W., Kwong, Ava, Lacey, James V., Lambrechts, Diether, Le Marchand, Loic, Li, Jingmei, Linet, Martha, Lo, Wing-Yee, Long, Jirong, Lophatananon, Artitaya, Mannermaa, Arto, Manoochehri, Mehdi, Margolin, Sara, Matsuo, Keitaro, Mavroudis, Dimitrios, Menon, Usha, Muir, Kenneth, Murphy, Rachel A., Nevanlinna, Heli, Newman, William G., Niederacher, Dieter, O’Brien, Katie M., Obi, Nadia, Offit, Kenneth, Olopade, Olufunmilayo I., Olshan, Andrew F., Olsson, Håkan, Park, Sue K., Patel, Alpa V., Patel, Achal, Perou, Charles M., Peto, Julian, Pharoah, Paul D. P., Plaseska-Karanfilska, Dijana, Presneau, Nadege, Rack, Brigitte, Radice, Paolo, Ramachandran, Dhanya, Rashid, Muhammad U., Rennert, Gad, Romero, Atocha, Ruddy, Kathryn J., Ruebner, Matthias, Saloustros, Emmanouil, Sandler, Dale P., Sawyer, Elinor J., Schmidt, Marjanka K., Schmutzler, Rita K., Schneider, Michael O., Scott, Christopher, Shah, Mitul, Sharma, Priyanka, Shen, Chen-Yang, Shu, Xiao-Ou, Simard, Jacques, Surowy, Harald, Tamimi, Rulla M., Tapper, William J., Taylor, Jack A., Teo, Soo Hwang, Teras, Lauren R., Toland, Amanda E., Tollenaar, Rob A. E. M., Torres, Diana, Torres-Mejía, Gabriela, Troester, Melissa A., Truong, Thérèse, Vachon, Celine M., Vijai, Joseph, Weinberg, Clarice R., Wendt, Camilla, Winqvist, Robert, Wolk, Alicja, Wu, Anna H., Yamaji, Taiki, Yang, Xiaohong R., Yu, Jyh-Cherng, Zheng, Wei, Ziogas, Argyrios, Ziv, Elad, Dunning, Alison M., Easton, Douglas F., Hemingway, Harry, Hamann, Ute, and Kuchenbaecker, Karoline B.

Published
2023
Full Text
View/download PDF

24. Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women

Author

Wang, Xiaoliang, Kapoor, Pooja Middha, Auer, Paul L, Dennis, Joe, Dunning, Alison M, Wang, Qin, Lush, Michael, Michailidou, Kyriaki, Bolla, Manjeet K, Aronson, Kristan J, Murphy, Rachel A, Brooks-Wilson, Angela, Lee, Derrick G, Cordina-Duverger, Emilie, Guénel, Pascal, Truong, Thérèse, Mulot, Claire, Teras, Lauren R, Patel, Alpa V, Dossus, Laure, Kaaks, Rudolf, Hoppe, Reiner, Lo, Wing-Yee, Brüning, Thomas, Hamann, Ute, Czene, Kamila, Gabrielson, Marike, Hall, Per, Eriksson, Mikael, Jung, Audrey, Becher, Heiko, Couch, Fergus J, Larson, Nicole L, Olson, Janet E, Ruddy, Kathryn J, Giles, Graham G, MacInnis, Robert J, Southey, Melissa C, Le Marchand, Loic, Wilkens, Lynne R, Haiman, Christopher A, Olsson, Håkan, Augustinsson, Annelie, Krüger, Ute, Wagner, Philippe, Scott, Christopher, Winham, Stacey J, Vachon, Celine M, Perou, Charles M, Olshan, Andrew F, Troester, Melissa A, Hunter, David J, Eliassen, Heather A, Tamimi, Rulla M, Brantley, Kristen, Andrulis, Irene L, Figueroa, Jonine, Chanock, Stephen J, Ahearn, Thomas U, García-Closas, Montserrat, Evans, Gareth D, Newman, William G, van Veen, Elke M, Howell, Anthony, Wolk, Alicja, Håkansson, Niclas, Anton-Culver, Hoda, Ziogas, Argyrios, Jones, Michael E, Orr, Nick, Schoemaker, Minouk J, Swerdlow, Anthony J, Kitahara, Cari M, Linet, Martha, Prentice, Ross L, Easton, Douglas F, Milne, Roger L, Kraft, Peter, Chang-Claude, Jenny, and Lindström, Sara

Subjects
Genetics, Cancer, Aging, Human Genome, Breast Cancer, Prevention, Estrogen, 2.1 Biological and endogenous factors, Aetiology, Breast, Breast Neoplasms, Estrogen Replacement Therapy, Female, Hormone Replacement Therapy, Humans, Male, Menopause, Risk Factors
Abstract

Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values

Published
2022

25. Secondary Breast Cancer Sociodemographic Characteristics and Survival by Age Group

Author

Sauder, Candice AM, Li, Qian, Bold, Richard J, Ruddy, Kathryn J, and Keegan, Theresa HM

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Aging, Breast Cancer, Adolescent, Adult, Aged, Breast Neoplasms, Female, Humans, Mastectomy, Neoplasms, Second Primary, Proportional Hazards Models, Registries, Young Adult, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundSecondary cancers account for 16% of all new cancer diagnoses, with breast cancer (BC) the most common secondary cancer. We have shown that secondary BC has unique characteristics and decreased survival compared with primary BC in adolescent and young adults (AYA; 15-39 years old). However, older BC populations are less well studied.MethodsFemales (age ≥ 15 years) diagnosed with primary BC during 1991-2015 (n = 377,167) and enrolled in the California Cancer Registry were compared with those with secondary BC (n = 37,625) by age (15-39, 40-64, ≥ 65 years). We examined BC-specific survival (BCSS) accounting for other causes of death as a competing risk using multivariable Cox proportional hazards regression.ResultsMost secondary BC patients were of older age (15-39, n = 777; 40-64, n = 15,848; ≥ 65, n = 21,000). Compared with primary BC treatment, secondary BCs were more often treated with mastectomy and less often with chemotherapy and/or radiation. BCSS was shorter in secondary BC patients than primary BC patients, but the survival difference between secondary and primary BC diminished with age [15-39 hazard ratio (HR): 2.09, 95% confidence interval (CI) 1.83-2.39; 40-64 HR: 1.51; 95% CI 1.44-1.58; ≥ 65 HR: 1.14; 95% CI 1.10-1.19]. Survival differences were most pronounced in women with hormone receptor positive disease and Hispanic and Asian/Pacific Islanders 40-64 years of age.ConclusionsWhen BC is diagnosed following a prior cancer of any organ site, BCSS is worse than when compared with patients for whom BC is the primary diagnosis, suggesting that we may need to tailor our treatments for women with secondary BC.

Published
2021

28. Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic Experience

Author

Jahan, Nusrat, Taraba, Jodi, Boddicker, Nicholas J, Giridhar, Karthik V., Leon-Ferre, Roberto A., Tevaarwerk, Amye J., Cathcart-Rake, Elizabeth, O'Sullivan, Ciara C., Peethambaram, Prema P., Hobday, Timothy J., Mina, Lida A., Batalini, Felipe, Advani, Pooja, Sideras, Kostandinos, Haddad, Tufia C., Ruddy, Kathryn J., Goetz, Matthew P., Couch, Fergus J., and Yadav, Siddhartha

Published
2024
Full Text
View/download PDF

29. Dose Deintensified 3-Day Photon, Proton, or Brachytherapy: A Nonrandomized Controlled Partial Breast Irradiation Trial

Author

Mutter, Robert W., Golafshar, Michael A., Buras, Matthew R., Comstock, Bryce P., Jacobson, Maddi, DeWees, Todd, Remmes, Nicholas B., Francis, Leah N., Boughey, Judy C., Ruddy, Kathryn J., McGee, Lisa A., Afzal, Arslan, Vallow, Laura A., Furutani, Keith M., Deufel, Christopher L., Shumway, Dean A., Kim, Haeyoung, Liu, Minetta C., Degnim, Amy C., Jakub, James W., Vern-Gross, Tamara Z., Wong, William W., Patel, Samir H., Vargas, Carlos E., Stish, Bradley J., Waddle, Mark R., Pafundi, Deanna H., Halyard, Michele Y., Corbin, Kimberly S., Hieken, Tina J., and Park, Sean S.

Published
2024
Full Text
View/download PDF

34. Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea.

Author

Ruddy, Kathryn J, Schaid, Daniel J, Batzler, Anthony, Cecchini, Reena S, Partridge, Ann H, Norman, Aaron, Fehrenbacher, Louis, Stewart, Elizabeth A, Trabuco, Emanuel, Ginsburg, Elizabeth, Couch, Fergus J, Fasching, Peter A, Vachon, Celine, and Ganz, Patricia A

Subjects
Aging, Cancer, Clinical Research, Adult, Amenorrhea, Anti-Mullerian Hormone, Antineoplastic Agents, Biomarkers, Breast Neoplasms, Chemotherapy, Adjuvant, Female, Humans, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Antimullerian hormone (AMH) is a promising biomarker for ovarian reserve. In this study, we assessed AMH before and 1 year after initiation of adjuvant chemotherapy on National Surgical Adjuvant Breast and Bowel Project (NSABP)/NRG Oncology B-47 in female participants aged 42 years and younger (median age = 39 years). At baseline, median AMH was 1.2 ng/mL; 13 (4.7%) values were less than 0.1 ng/mL (the threshold for detectable levels, in the perimenopause and menopause range), and 57 values (20.6%) were less than 0.5 ng/mL. At 1 year, 215 (77.6%) were less than 0.1 ng/mL, and 264 (95.3%) were less than 0.5 ng/mL. Postchemotherapy menses were reported by 46.2% of participants. Multivariable logistic regression found that the odds of having postchemotherapy menses increased with younger age, higher body mass index, and higher prechemotherapy AMH, but not by trastuzumab administration or by the choice of chemotherapy (doxorubicin-cyclophosphamide followed by paclitaxel vs docetaxel-cyclophosphamide). We conclude that higher prechemotherapy AMH predicts a lower risk of chemotherapy-induced amenorrhea and that AMH 1 year after chemotherapy initiation is not informative in this setting because it is likely to be very low.

Published
2021

35. Genome-Wide Interaction Analysis of Menopausal Hormone Therapy Use and Breast Cancer Risk Among 62,370 Women

Author

Wang, Xiaoliang, Kapoor, Pooja Middha, Auer, Paul L, Dennis, Joe, Dunning, Alison M, Wang, Qin, Lush, Michael, Michailidou, Kyriaki, Bolla, Manjeet K, Aronson, Kristan J, Murphy, Rachel A, Brooks-Wilson, Angela, Lee, Derrick G, Cordina-Duverger, Emilie, Guénel, Pascal, Truong, Thérèse, Mulot, Claire, Teras, Lauren R, Patel, Alpa V, Dossus, Laure, Kaaks, Rudolf, Hoppe, Reiner, Lo, Wing-Yee, Brüning, Thomas, Hamann, Ute, Czene, Kamila, Gabrielson, Marike, Hall, Per, Eriksson, Mikael, Jung, Audrey, Becher, Heiko, Couch, Fergus J, Larson, Nicole L, Olson, Janet E, Ruddy, Kathryn J, Giles, Graham G, MacInnis, Robert J, Southey, Melissa C, Marchand, Loic Le, Wilkens, Lynne R, Haiman, Christopher A, Olsson, Håkan, Augustinsson, Annelie, Krüger, Ute, Wagner, Philippe, Scott, Christopher, Winham, Stacey J, Vachon, Celine M, Perou, Charles M, Olshan, Andrew F, Troester, Melissa A, Hunter, David J, Eliassen, A Heather, Tamimi, Rulla M, Brantley, Kristen, Andrulis, Irene L, Figueroa, Jonine, Chanock, Stephen J, Ahearn, Thomas U, García-Closas, Montserrat, Evans, Gareth D, Newman, William G, Veen, Elke M van, Howell, Anthony, Wolk, Alicja, Håkansson, Niclas, Anton-Culver, Hoda, Ziogas, Argyrios, Jones, Michael E, Orr, Nick, Schoemaker, Minouk J, Swerdlow, Anthony J, Kitahara, Cari M, Linet, Martha, Prentice, Ross L, Easton, Douglas F, Milne, Roger L, Kraft, Peter, Chang-Claude, Jenny, and Lindström, Sara

Subjects
Cancer, Prevention, Breast Cancer, Genetics, Human Genome, Aging, Estrogen, Aetiology, 2.1 Biological and endogenous factors, Good Health and Well Being
Abstract

Abstract Background: Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. Methods: We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values

Published
2021

36. Postmastectomy Intensity Modulated Proton Therapy: 5-Year Oncologic and Patient-Reported Outcomes

Author

Gao, Robert W., Mullikin, Trey C., Aziz, Khaled A., Afzal, Arslan, Smith, Na L., Routman, David M., Gergelis, Kimberly R., Harmsen, William S., Remmes, Nicholas B., Tseung, Hok Seum Wan Chan, Shiraishi, Satomi S., Boughey, Judy C., Ruddy, Kathryn J., Harless, Christin A., Garda, Allison E., Waddle, Mark R., Park, Sean S., Shumway, Dean A., Corbin, Kimberly S., and Mutter, Robert W.

Published
2023
Full Text
View/download PDF

37. Conventional versus hypofractionated postmastectomy proton radiotherapy in the USA (MC1631): a randomised phase 2 trial

Author

Mutter, Robert W, Giri, Sharmila, Fruth, Briant F, Remmes, Nicholas B, Boughey, Judy C, Harless, Christin A, Ruddy, Kathryn J, McGee, Lisa A, Afzal, Arslan, Gao, Robert W, Shumway, Dean A, Vern-Gross, Tamara Z, Villarraga, Hector R, Kenison, Stephanie L, Kang, Yixiu, Wong, William W, Stish, Bradley J, Merrell, Kenneth W, Yan, Elizabeth S, Park, Sean S, Corbin, Kimberly S, and Vargas, Carlos E

Published
2023
Full Text
View/download PDF

38. Survivorship, Version 1.2021.

Author

Tevaarwerk, Amye, Denlinger, Crystal S, Sanft, Tara, Ansbaugh, Shannon M, Armenian, Saro, Baker, K Scott, Broderick, Gregory, Day, Andrew, Demark-Wahnefried, Wendy, Dickinson, Kristin, Friedman, Debra L, Ganz, Patricia, Goldman, Mindy, Henry, Norah Lynn, Hill-Kayser, Christine, Hudson, Melissa, Khakpour, Nazanin, Koura, Divya, McDonough, Allison L, Melisko, Michelle, Mooney, Kathi, Moore, Halle CF, Moryl, Natalie, Moslehi, Javid J, O'Connor, Tracey, Overholser, Linda, Paskett, Electra D, Patel, Chirayu, Peterson, Lindsay, Pirl, William, Rodriguez, M Alma, Ruddy, Kathryn J, Schapira, Lidia, Shockney, Lillie, Smith, Sophia, Syrjala, Karen L, Zee, Phyllis, McMillian, Nicole R, and Freedman-Cass, Deborah A

Subjects
Health Services and Systems, Nursing, Health Sciences, Cancer, Rehabilitation, Prevention, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, Adult, Cancer Survivors, Humans, Mass Screening, Neoplasms, Survivors, Survivorship, Oncology & Carcinogenesis, Oncology and carcinogenesis, Health services and systems
Abstract

The NCCN Guidelines for Survivorship are intended to help healthcare professionals working with cancer survivors to ensure that each survivor's complex and varied needs are addressed. The Guidelines provide screening, evaluation, and treatment recommendations for consequences of adult-onset cancer and its treatment; recommendations to help promote healthful lifestyle behaviors, weight management, and immunizations in survivors; and a framework for care coordination. This article summarizes the recommendations regarding employment and return to work for cancer survivors that were added in the 2021 version of the NCCN Guidelines.

Published
2021

42. Long-term outcomes of intraoperatively-placed applicator brachytherapy for rapid completion of breast conserving treatment: An analysis of a prospective registry data

Author

Kim, Haeyoung, Hieken, Tina J., Abraha, Feven, Jakub, James W., Corbin, Kimberly S., Furutani, Keith M., Boughey, Judy C., Stish, Bradley J., Deufel, Christopher L., Degnim, Amy C., Shumway, Dean A., Ahmed, Safia K., Piltin, Mara A., Sandhu, Nicole P., Conners, Amy L., Ruddy, Kathryn J., Mutter, Robert W., and Park, Sean S.

Published
2023
Full Text
View/download PDF

44. Follow-up care for breast cancer survivors

Author

Ruddy, Kathryn J, Herrin, Jeph, Sangaralingham, Lindsey, Freedman, Rachel A, Jemal, Ahmedin, Haddad, Tufia C, Allen, Summer V, Hieken, Tina, Boughey, Judy C, Ganz, Patricia A, Havyer, Rachel D, and Shah, Nilay D

Subjects
Rehabilitation, Breast Cancer, Cancer, Aging, Health Services, Clinical Research, Prevention, 7.3 Management and decision making, Management of diseases and conditions, Aftercare, Breast Neoplasms, Cancer Survivors, Disease Management, Female, Humans, Practice Guidelines as Topic, Public Health Surveillance, Registries, Retrospective Studies, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

Breast cancer survivorship guidelines recommend at least annual follow-up visits, yet the degree to which this occurs in clinical practice is uncertain. Claims data from a US commercial insurance database (OptumLabs) were used to identify women treated with curative intent surgery for newly diagnosed breast cancer between 2006 and 2014. In 25 035 women, median follow-up was 3 years. In the second year after surgery, 9.6% of the patients did not visit a primary care provider, an oncologist, or a surgeon (guideline-nonadherent). The guideline-nonadherent proportion increased from 7.8% in women diagnosed in 2006 to 12.2% in those diagnosed in 2014 (two-sided Wald P

Published
2020

49. Acceptability of a companion patient guide to support expert consensus guidelines on surveillance mammography in older breast cancer survivors

Author

Freedman, Rachel A., Revette, Anna C., Gagnon, Haley, Perilla-Glen, Adriana, Kokoski, Molly, Hussein, Saida O., Leone, Erin, Hixon, Nicole, Lovato, Rebeka, Loeser, Wendy, Lin, Nancy U., Minami, Christina A., Canin, Beverly, LeStage, Barbara, Faggen, Meredith, Poorvu, Philip D., McKenna, Jennifer, Ruddy, Kathryn J., Keating, Nancy L., and Schonberg, Mara A.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results